Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kobayashi Kako to Withdraw Marketing License on April 1
Over two years after a high-profile sleep-inducer contamination scandal, Kobayashi Kako will discontinue its operations as a pharmaceutical marketing authorization (MA) holder, as of April 1. The generic maker said on March 22 that it will delist all products registered…
To read the full story
Related Article
- Kobayashi Kako to Withdraw Marketing License Next April
June 28, 2022
- Kobayashi Kako Ditches Turnaround Plan with Manufacturing Transfer to Sawai
December 7, 2021
- Kobayashi Kako Slapped with Record 116-Day Business Suspension
February 9, 2021
BUSINESS
- Toho Invests in Keio Offshoot AdipoSeeds
October 19, 2026
- Amgen, JASSO Team Up on Obesity Research and Care
October 19, 2026
- Sanwa Kagaku to Resume Kumamoto Production on October 19
October 19, 2026
- J&J Launches Stelara SC Vial for Pediatric Crohn’s Disease
October 19, 2026
- M3’s MR-kun Hit by Data Breach, Pharma Staff and Doctors Exposed
October 16, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…